KMCRIC

Treatment of primary chronic glomerulonephritis with Rehmannia glutinosa acteosides in combination with the Angiotensin receptor blocker irbesartan: a randomized controlled trial.

Qiu H, Fu P, Fan W, Zuo C, Feng P, Shi P, Cao L, Liu F, Zhou L, Chen F, Zhong H, Gou Z, Liang Y, Shi M.

Phytother Res.

2014

28(1)

132-6.

10.1002/ptr.4973.

23519822

http://www.ncbi.nlm.nih.gov/pubmed/23519822

Adult
Angiotensin II Type 1 Receptor Blockers/therapeutic use
Biphenyl Compounds/therapeutic use*
Blood Pressure/drug effects
Female
Glomerulonephritis/drug therapy*
Glucosides/therapeutic use*
Humans
Male
Middle Aged
Phenols/therapeutic use*
Proteinuria/drug therapy
Rehmannia/chemistry*
Tetrazoles/therapeutic use*

Rehmannia glutinosa acteosides; Traditional Chinese Medicine; chronic disease; general acteoside in extract of Rehmanniae leaves; randomized clinical trials

지황의 acteosides; 중의학; 만성 질환; 지황잎 추출물의 일반 아세토사이드; 무작위배정 비교 임상시험

KMCRIC 비평 보기 +

This study aims to assess the efficacy and safety of Rehmannia glutinosa acteosides used in combination with the angiotensin receptor blocker irbesartan to treat primary chronic glomerulonephritis. A total of 479 patients diagnosed with primary chronic glomerulonephritis were recruited from outpatient clinics and were randomly assigned to the treatment group (Rehmannia glutinosa acteosides, two 200-mg capsules, bid; and irbesartan, one 150-mg tablet, qd) or the control group (irbesartan, one 150-mg tablet, qd). The primary outcome was 24-h urinary protein. Secondary outcome measures included blood pressure, estimated glomerular filtration rate, erythrocyturia, serum alanine aminotransferase, aspartate transaminase and electrolytes. After 8 weeks of treatment, the treatment group showed a mean reduction in 24-h proteinuria of 36.42% compared to baseline, which was significantly higher than the mean reduction from baseline of 27.97% in the control group (P = 0.0278).Adverse drug reactions occurred at a similarly low rate in the treatment group (0.4%) and control group (1.2%, P = 0.3724). In the treatment of chronic glomerulonephritis, the combination of Rehmannia glutinosa acteosides and irbesartan can reduce proteinuria more effectively than irbesartan alone.

영어